Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
Aim. To perform health-economic evaluation of trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer and CNS metastases. Materials and methods. Cost-effectiveness analysis along with sensitivity analysis and budget impact analysis were performed. Direct medical costs and indirect costs (...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2018-05-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/82 |